Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A2 Allele Polymorphism of the CYP17 Gene and Prostate Cancer Risk in an Iranian Population

  • Karimpur-Zahmatkesh, Arezu (Medical Genetics Department, Shahid Beheshti of Medical Science University) ;
  • Farzaneh, Farah (Department of Ob And Gyn, Shahid Beheshti of Medical Science University) ;
  • Pouresmaeili, Farkhondeh (Medical Genetics Department, Shahid Beheshti of Medical Science University) ;
  • Hosseini, Jalil (Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti of Medical Science University) ;
  • Azarghashb, Eznollah (Social Medical Department, Shahid Beheshti of Medical Science University) ;
  • Yaghoobi, Mohammad (Urology Department, Shahid Beheshti of Medical Science University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Studies have shown that alterations of steroid hormone metabolism, particularly involving testosterone, affect the risk of prostate cancer. Therefore, genetic variation in genes of enzymes which are involved could be of importance. The gene most interest is CYP17, whose enzyme product has an essential role in testosterone hormone synthesis. Some studies have indicated that the A2 allele polymorphism of CYP17 associated with increased risk of prostate cancer that could be affected by ethnicity. Therefore, the aim of this study was determination of presence or absence of the A2 allele in patients with prostate cancer. Materials and Methods: We studied the association of A2 allele and prostate cancer among 74 patients with prostate cancer and 128 healthy men which were referred to hospitals of SBMU. Results: This study revealed a significant association between prostate cancer risk and the A2 allele in an Iranian population so that A1A2 and A2A2 genotypes were more common in cases than controls with P-values of 0.029 and 0.010, respectively. Conclusions: Results of our study support a possible role of the A2 allele in sporadic prostate cancer development in Iran, in line with findings elsewhere.

Keywords

References

  1. Alberti C (2010). Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci, 14, 31-41.
  2. Antognelli C, Mearini L, Talesa VN, et al (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. The Prostate, 63, 240-51. https://doi.org/10.1002/pros.20184
  3. Barnes HJ, Arlotto MP, Waterman MR, et al (1991). Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proceedings of the National Academy of Sciences, 88, 5597. https://doi.org/10.1073/pnas.88.13.5597
  4. Bergman-Jungestrom M, Gentile M, Lundin AC, et al (1999). Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer, 84, 350-3. https://doi.org/10.1002/(SICI)1097-0215(19990820)84:4<350::AID-IJC3>3.0.CO;2-L
  5. Camp NJ, Tavtigian SV (2002). Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Human Genetics, 71, 1475. https://doi.org/10.1086/344516
  6. Carey AH, Waterworth D, Patel K, et al (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics, 3, 1873-6. https://doi.org/10.1093/hmg/3.10.1873
  7. Chen H, Griffin A, Wu Y, et al (2003). RNASEL mutations in hereditary prostate cancer. J Medical Genetics, 40, 21. https://doi.org/10.1136/jmg.40.3.e21
  8. Cicek MS, Conti DV, Curran A, et al (2003). Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. The Prostate, 59, 69-76.
  9. Fan YS, Sasi R, Lee C, et al (1992). Localization of the human CYP17 gene (cytochrome P45017 [alpha]) to 10q24. 3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics, 14, 1110-1. https://doi.org/10.1016/S0888-7543(05)80140-5
  10. Feigelson HS, Coetzee GA, Kolonel LN, et al (1997). A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063-5.
  11. Gsur A, Bernhofer G, Hinteregger S, et al (2000). A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer, 87, 434-7. https://doi.org/10.1002/1097-0215(20000801)87:3<434::AID-IJC19>3.0.CO;2-G
  12. Gsur A, Feik E, Madersbacher S, et al. (2004). Genetic polymorphisms and prostate cancer risk. World J Urol, 21, 414-23. https://doi.org/10.1007/s00345-003-0378-4
  13. Habuchi T, Liqing Z, Suzuki T, et al (2000). Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60, 5710-3.
  14. Haiman CA, Hankinson SE, Spiegelman D, et al (1999). The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res, 59,1015-20.
  15. Haiman CA, Stampfer MJ, Giovannucci E, et al (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiology Biomarkers &Prev, 10, 743-8.
  16. Hong WK, Bast RC, Hait W, et al. (2010). Holland Frei cancer medicine eight, Pmph USA Ltd.
  17. Lunn RM, Bell DA, Mohler JL, et al (1999). Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 20, 1727-31. https://doi.org/10.1093/carcin/20.9.1727
  18. Madigan MP, Gao YT, Deng J, et al (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population based study in China. Int J Cancer, 107, 271-5. https://doi.org/10.1002/ijc.11378
  19. Ntais C, Polycarpou A, Ioannidis JPA, et al (2003). Association of the CYP17 gene polymorphism with the risk of prostate cancer a meta-analysis. Cancer Epidemiol Biomarkers &Prev, 12, 120-6.
  20. Ntais C, Polycarpou A, Tsatsoulis A, et al (2003). Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol, 149, 469-77. https://doi.org/10.1530/eje.0.1490469
  21. Picado-Leonard J, Miller Wl (1987). Cloning and Sequence of the Human Gene for P450cl7 (Steroid 17$\alpha$-Hydroxylase/17, 20 Lyase): Similarity with the Gene for P450c21. DNA, 6, 439-48. https://doi.org/10.1089/dna.1987.6.439
  22. Sadjadi A, Nooraie M, Ghorbani A, et al. (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5.
  23. Sarma AV, Dunn RL, Lange LA, et al (2008). Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF 1, and IGFBP 3 and prostate cancer risk in African American men: The Flint men's health study. The Prostate, 68, 296-305. https://doi.org/10.1002/pros.20696
  24. Sobti R, Onsory K, Al-Badran AI, et al (2006). CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biology, 25, 287-94. https://doi.org/10.1089/dna.2006.25.287
  25. Sobti RC, Gupta L, Thakur H, et al (2009). CYP17 gene polymorphism and its association in north Indian prostate cancer patients. Anticancer Res, 29, 1659-63.
  26. Souiden Y, Mahdouani M, Chaieb K, et al (2010). CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Cancer Epidemiology, 35, 480-4.
  27. Stanford JL, Noonan EA, Iwasaki L, et al (2002). A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiology Biomarkers Prev, 11, 243-7.
  28. Yamada Y, Watanabe M, Murata M, et al (2001). Impact of genetic polymorphisms of 17-hydroxylase cytochrome P 450 (CYP17) and steroid 5$\alpha$ reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer, 92, 683-6. https://doi.org/10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4
  29. Yang J, Wu H, Zhang W, et al (2006). Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci, 11, 2052-60.

Cited by

  1. Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1255
  2. Association of rs1042522 Polymorphism with Increased Risk of Prostate Adenocarcinoma in the Pakistani Population and its HuGE Review vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3973
  3. Quantitative Assessment of the Association Between CYP17 rs743572 Polymorphism and Prostate Cancer Risk vol.71, pp.2, 2015, https://doi.org/10.1007/s12013-014-0297-6